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Background: With the recent growth of interest in cell-based therapies and radiolabeled cell products, there is a
need to develop more robust cell labeling and imaging methods for in vivo tracking of living cells. This study
describes evaluation of a novel cell labeling approach with the positron emission tomography (PET) isotope 89Zr
(T1/2 = 78.4 h).
89Zr may allow PET imaging measurements for several weeks and take advantage of the high
sensitivity of PET imaging.
Methods: A novel cell labeling agent, 89Zr-desferrioxamine-NCS (89Zr-DBN), was synthesized. Mouse-derived melanoma
cells (mMCs), dendritic cells (mDCs), and human mesenchymal stem cells (hMSCs) were covalently labeled with
89Zr-DBN via the reaction between the NCS group on 89Zr-DBN and primary amine groups present on cell surface
membrane protein. The stability of the label on the cell was tested by cell efflux studies for 7 days. The effect of labeling
on cellular viability was tested by proliferation, trypan blue, and cytotoxicity/apoptosis assays. The stability of label
was also studied in in vivo mouse models by serial PET scans and ex vivo biodistribution following intravenous and
intramyocardial injection of 89Zr-labeled hMSCs. For comparison, imaging experiments were performed after
intravenous injections of 89Zr hydrogen phosphate (89Zr(HPO4)2).
Results: The labeling agent, 89Zr-DBN, was prepared in 55% ± 5% decay-corrected radiochemical yield measured by
silica gel iTLC. The cell labeling efficiency was 30% to 50% after 30 min labeling depending on cell type. Radioactivity
concentrations of labeled cells of up to 0.5 MBq/106 cells were achieved without a negative effect on cellular viability.
Cell efflux studies showed high stability of the radiolabel out to 7 days. Myocardially delivered 89Zr-labeled hMSCs
showed retention in the myocardium, as well as redistribution to the lung, liver, and bone. Intravenously administered
89Zr-labeled hMSCs also distributed primarily to the lung, liver, and bone, whereas intravenous 89Zr(HPO4)2 distributed
to the liver and bone with no activity in the lung. Thus, the in vivo stability of the radiolabel on the hMSCs was
evidenced.
Conclusions: We have developed a robust, general, and biostable 89Zr-DBN-based cell labeling strategy with promise
for wide applications of PET-based non-invasive in vivo cell trafficking.
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With the growth of interest in cell-based therapies, there is
a need to develop more sensitive, robust, and quantitative
imaging methods for in vivo tracking of living cells. A num-
ber of radioisotopic cell labeling methods have traditionally
been used for single-photon emission computerized tomog-
raphy (SPECT) and positron emission tomography (PET)
imaging-based cell tracking [1]. However, a PET-based ap-
proach would offer superior quantification and imaging sen-
sitivity characteristics over a SPECT-based approach, which
are critical for tracking of small numbers of administered
cells [1]. In this regard, 89Zr has emerged as an attractive
PET radionuclide for cell labeling applications due to its
high spatial resolution and 78.4-h half-life that may allow
monitoring of administered cells up to a 2- to 3-week
period.
A variety of cell labeling strategies have been forwarded,
including transport of a radiometal (111In, 99mTc, 64Cu,
89Zr) into cells in conjunction with oxine, hexamethylpro-
pyleneamine oxime (HMPAO), pyruvaldehyde-bis(N4-
methylthiosemicarbazone) (PTSM), or protamine sulfate,
or antibody-based labeling (Table 1) [1-11]. In the transport
approach, after entry into the cell, the radiometal dissociates
and binds to a variety of intracellular biomolecules. The
major drawback of this approach is that appreciable efflux
of sequestered radioactivity is observed post-labeling. The
extent of efflux has been as high as 70% to 80% in 24 to
96 h as reported for 111In-oxine-labeled lymphocytes [4],
111In-oxine-labeled hematopoietic progenitor cells [5], and
64Cu-PTSM-labeled C6 glioma cells [7]. Recently, 89Zr-oxineTable 1 Present direct radioisotopic cell labeling methods
Isotope-compound/T1/2 Cells labeled Labeling and im
111In-oxine/67.4 h Leukocytes Approximately 8
Lymphocytes Significant efflux
in 24 h) and HPC
HPCs Suboptimal imag
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Significant efflux
64Cu-TETA- or 89Zr-DFO-antiCD45/
12.7 h (64Cu), 78.4 h (89Zr)
hPBSCs Binds to only CD
Approach was su
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Loss of cell viabi





Efflux rate not re
HPCs, hematopoietic progenitor cells; hPBSCs, human peripheral blood stem cells.has been reported as a labeling molecule but like 111In-
oxine, it also undergoes efflux (10% to 29% at 24 h in mac-
rophages, breast cancer cells, and myeloma cells [9] and
70% to 80% at 24 h in natural killer cells [10]). Efflux of ra-
diolabel significantly limits monitoring cell trafficking over
longer observational periods. Cells have also been labeled
with 18 F-FDG [12-16] (T1/2 = 109.8 min),
99mTc-HMPAO
[17] (T1/2 = 6 h), and
64Cu-labeled anti-CD45 [8] (T1/2 =
12.7 h), but the short half-lives of these radioisotopes limit
their utility for cell tracking to shorter observational pe-
riods. An alternative antibody-based stem cell labeling
method employed 89Zr-labeled anti-CD45 for ex vivo label-
ing of stem cells expressing CD45 membrane protein.
However, this radiotracer yielded poor in vivo imaging
characteristics, possibly due to insufficient CD45 molecules
on the plasma membrane of stem cells [8].
In this study, we propose a novel cell labeling strategy
that covalently binds a 89Zr-DFO-labeled agent to cell
surface proteins independent of cell type. The novel
method employs the two-step process (Figure 1): 1)
preparation of 89Zr-labeled p-isothiocyanato-benzyl-
desferrioxamine (89Zr-DBN) and 2) random labeling of
primary amines of cell surface proteins with 89Zr-DBN.
We have evaluated this labeling strategy in three cell
types: mouse melanoma cells (mMCs), human mesen-
chymal stem cells (hMSCs), and mouse dendritic cells
(mDCs). The labeled cells were evaluated for 7 days
post-labeling for label retention and probable changes
in cell proliferation, cell viability, and degree of apop-
tosis in radiolabeled cells as compared to theiraging characteristics Reference
0% cell labeling yield in 30 min [2-6]
rate reported in lymphocytes (approximately 70% effluxed
s (approximately 75% effluxed in 96 h)
e quality and sensitivity
labeling yield in 5 h [7]
rate from cells (approximately 80% effluxed in 24 h)
45 membrane protein expressing cells [8]
boptimal possibly due to insufficient CD45 molecules on
brane of stem cells
2% cell labeling yield in 30 min [9,10]
rate reported for myeloma cells (29% effluxed in 24 h) and
(70% to 80% effluxed in 7 days)
lity possibly due to oxine exposure
4% cell labeling yield (dendritic cells) in 30 min [11]
2% cell labeling yield (T lymphocytes) in 30 min
non-specific intracellular biomolecules
ported
Figure 1 Scheme for synthesis of 89Zr-DBN and cell labeling.
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were further tested for imaging characteristics and sta-
bility of radiolabel in an in vivo mouse model.
Methods
Cell culture
B16-F10 mMCs from ATCC, Manassas, VA, USA, hMSCs
from patients, and JAWSII mDCs from ATCC, Manassas,
VA, USA, were used for evaluating the 89Zr-DBN-based la-
beling method. The mMCs and hMSCs were cultured in
complete Dulbecco’s modified Eagle’s medium (DMEM)
(DMEM+ 10% FBS), and mDCs were cultured in complete
alpha MEM (alpha MEM+ 4 mM L-glutamine + 1 mM so-
dium pyruvate + 5 ng/mL murine GM-CSF + 20% FBS).
The cultures were maintained in a humidified cell culture
chamber (21% O2, 74% N2, 5% CO2) at 37°C.
Production and isolation of 89Zr
89Zr4+ was produced in aqueous solution through the
89Y(p,n)89Zr nuclear reaction using a solution target
containing yttrium nitrate and dilute nitric acid [18].
The 89Zr4+ was isolated from 89Y3+ using a hydroxamate
resin-based purification method [18,19] with the excep-
tion that the final elution of 89Zr4+ off the hydroxamate
resin was performed with an appropriate volume of
1.2 M K2HPO4/KH2PO4 buffer (pH 3.5). The K2HPO4/
KH2PO4 buffer was allowed to sit on the column for
30 min before elution to promote release of 89Zr as zir-
conium hydrogen phosphate, 89Zr(HPO4)2, from the col-
umn. The elution percentage of 89Zr from the column
was approximately 89% collected in four fractions of
0.5 mL each.Synthesis of 89Zr-DBN
The eluted 89Zr(HPO4)2 solution (120 μL) was neutral-
ized to pH 7.8 with 100 μL 1 M HEPES-KOH buffer
(pH 7.5) and 65 μL 1 M K2CO3. To this, 4 μL 5 mM
DFO-Bz-NCS in DMSO (Macrocylics, Dallas, TX, USA)
was added, and chelation of 89Zr4+ proceeded at 37°C
for 1 h in a thermomixer at 550 rpm. Chelation effi-
ciency was determined by silica gel iTLC (Agilent Tech-
nologies, Santa Clara, CA, USA) with 50 mM DTPA
pH 7 as the mobile phase. 89Zr-DBN showed an Rf = 0,
whereas 89Zr(HPO4)2 had an Rf = 0.9.
Labeling of cells with 89Zr(HPO4)2 and
89Zr-DBN
The adherent cells were trypsinized and washed once with
PBS and twice with HEPES buffered GIBCO Hanks
Balanced Salt solution buffered (Thermo Fisher, Waltham,
MA, USA) (H-Hank’s Balanced Salt Solution (HBSS),
pH 7.5. The cell labeling reaction was performed with ap-
proximately 6 × 106 cells in 500 uL H-HBSS at pH 7.5. To
this, either 100 μL 89Zr(HPO4)2 (approximately 6 MBq) or
100 uL 89Zr-DBN (approximately 6 MBq) was added and
was allowed to incubate at 37°C for 30 min on a shaker
for cell labeling. After incubation, the cells were washed
four times with appropriate volume of complete medium.
The final labeling efficiency was calculated from the radio-
activity bound to cells after all the washes.
Incorporation of 89Zr-DBN in protein fraction
To understand the subcellular localization of the label,
incorporation of 89Zr-DBN into different protein frac-
tions in mMCs, hMSCs, and mDCs was evaluated using
a subcellular protein fractionation kit (Piercenet Thermo
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labeling. The cytosolic proteins, hydrophobic membrane
proteins, nuclear proteins, and cytoskeletal proteins were
isolated, and each protein fraction was counted for
radioactivity using a 2480 Wizard2 automatic gamma
counter (PerkinElmer, Waltham, MA, USA).Efflux of 89Zr-DBN from labeled cells
To determine cellular efflux, 0.3 × 106 89Zr-labeled cells
were plated into each well of a six-well culture plate.
The medium was replaced with fresh medium daily for
7 days, and radioactivity in the replaced medium was
counted. For mDCs with mix of adherent and suspen-
sion cells, the plate was centrifuged at 1,000 rpm for
10 min before replacing the medium to avoid loss of un-
attached 89Zr-labeled cells.CyQUANT cellular proliferation assay
The effect of radiolabeling on cellular proliferation was
assessed by the CyQUANT DNA content assay (Thermo
Fisher, Waltham, MA, USA). A known number of un-
labeled and 89Zr-labeled cells (approximately 104 cells/
well) were plated in 21 wells of a 96-well culture plate
and maintained at 37°C in a CO2 incubator. The amount
of DNA in each well was quantified from absorbance
values as a surrogate marker of the number of cells
present. The culture medium was replaced daily. The
CyQUANT assay was performed for three wells per day
over 5 days.Trypan blue exclusion assay cellular viability test
The effect of labeling on cellular viability was assessed
using trypan blue exclusion assay test within 1 h of la-
beling, third and seventh day post-labeling. The culture
medium was replaced daily and maintained at 37°C in a
CO2 incubator. Unlabeled cells served as control.ApoTox-Glo viability/cytotoxicity and apoptosis assay
The effect of radiolabeling on cellular viability was also
assessed using the ApoTox-Glo viability, cytotoxicity,
and caspase 3/7 apoptosis assay (Promega Corporation,
Madison, WI, USA). Unlabeled cells served as control. A
known number of unlabeled and 89Zr-labeled cells (ap-
proximately 104/well) were plated in a 96-well culture
plate. The culture medium was replaced daily and main-
tained at 37°C in a CO2 incubator. At day 7, cell viabil-
ity, cytotoxicity, and apoptosis were quantified in
triplicate using the ApoTox-Glo assay. As positive con-
trols, cells were incubated with 30 μg/mL digitonin for
30 min for the viability and cytotoxicity assays, while
2 μM staurosporine was added for 16 h for the caspase
3/7 dependent apoptosis assay.PET imaging and ex-vivo biodistribution of 89Zr-labeled
cells and 89Zr(HPO4)2
Experiments were performed with 2-month-old athymic
nude Foxn1nu mice (Harlan Laboratories, Inc., Indianapolis,
IN, USA). 89Zr(HPO4)2 (approximately 0.074 MBq) or
89Zr-
labeled cells (2 × 105 cells with radioactivity concentration
approximately 0.37 MBq/1 × 106 cells) were injected intra-
venously through a tail vein. On days 2, 4, and 7, the mice
were anesthetized under 1% to 2% isoflurane and underwent
PET imaging using a small animal PET/X-RAY system
(Sofie BioSystems Genesys4, Culver City, CA, USA). At day
7, the mice were sacrificed and tissues were extracted and
radioactivity counted using a gamma counter to evaluate the
biodistribution of 89Zr radioactivity. PET images were nor-
malized to units of standardized uptake value (SUV) = (ac-
tivity concentration in tissue / (injected dose/g whole body
wt.)) and presented as a coronal sectional images.In vivo tracking of stem cell engraftment in ischemia/
reperfusion mouse model
Athymic nude Foxn1nu mice (2 months old) were anes-
thetized under 1% to 2% isoflurane and placed on a
heating pad maintained at 37°C. Respiratory and heart
rates were monitoring continually. After intubation,
mechanical ventilation and intercostal block of bupiva-
caine and lidocaine, an incision was made in through
the fourth or fifth intercostal space for access into the
thoracic space, the heart was exposed and the pericar-
dium was incised anterior and parallel to the phrenic
nerve. With visualization of the coronary vasculature,
the left coronary artery was ligated to induce myocardial
ischemia at the anterior wall of the left ventricle. One
hour after the coronary ligation, the suture was untied
for reperfusion. Myocardial reperfusion was confirmed
by color change of the left ventricle and electrocardio-
graphic changes. During reperfusion, 89Zr-labeled cells
(2 × 105 cells with radioactivity concentration approxi-
mately 0.37 MBq/106 cells) were injected at four sites
within the ischemic region. After myocardial injection,
the intercostal space, the chest musculature, and the
skin were closed with a 7-0 Ethilon suture. The animals
were imaged at day 2, day 5, and day 7 using small
animal PET/X-RAY system (Sofie BioSystems Genesys4,
Culver City, CA, USA). At day 7, the mice were sacrificed
and tissues were extracted and radioactivity counted using
gamma counter to evaluate cell trafficking. PET images
were normalized to units of SUV and presented as coronal
sectional images.Statistical analysis
The data were compared using unpaired Student’s t-test
analyses. Differences were regarded as statistically signifi-
cant for p < 0.05.
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Synthesis of 89Zr-DBN and cell labeling studies
89Zr hydrogen phosphate was readily chelated by DFO-
NCS to form 89Zr-DBN, with radiolabeling efficiency of
55% ± 5% after 1 h of reaction. This reaction mixture was
then used directly for labeling of cells. The cell labeling ef-
ficiency using 89Zr-DBN was approximately 30% to 50%
as determined by cell-bound radioactivity. Radioactivity
concentrations of 0.50 ± 0.10, 0.47 ± 0.10, and 0.39 ±
0.20 MBq/106 cells were achieved when 6 × 106 cells were
incubated for 30 min with approximately 6 MBq 89Zr-
DBN with mMCs, hMSCs, and mDCs, respectively. In
contrast, no cell labeling was observed using 89Zr(HPO4)2.
Cellular proliferation and viability studies
The CyQUANT proliferation assay showed no difference in
proliferation rate between unlabeled and 89Zr-labeled cells
(Figure 2). Trypan blue cell viability tests were performed
on radiolabeled cells immediately after labeling and up to
7 days post-labeling and compared with unlabeled cells. No
change was observed in number of dead cells (blue-stained
cells) over live cells (unstained cells) in both 89Zr-labeled
and unlabeled cells, with percentage of dead cells <5% in all
days tested.
ApoTox-Glo viability/cytotoxicity and apoptosis assay
The ApoTox-Glo assay showed no loss in cellular viability
and no increase in cytotoxicity or apoptosis in radiolabeled
cells as illustrated in Figure 3. Viability was lost, and cyto-
toxicity enhanced when 30 μg/mL digitonin was added to
cells (positive control), and apoptosis was increased with the
addition of 2 μM staurosporine (positive control).
Subcellular distribution of 89Zr radioactivity
At days 1, 4, and 7 after 89Zr labeling of mMCs, hMSCs,
and mDCs, subcellular protein fractionation of the cellsFigure 2 Comparison of cell population doubling times for
89Zr-labeled and unlabeled mMCs, hMSCs and mDCs. The cells
were plated at appropriate cell number at day 3, and CyQUANT assay
was performed at day 7 post-labeling. No significant differences were
observed between radiolabeled and unlabeled cells. Values are shown
as mean ± standard deviation, n = 3.was performed. 89Zr radioactvity was incorporated pre-
dominantly (>99%) in hydrophobic membrane protein
fraction of all cell types studied, strongly supporting the
proposed mechanism of reaction of 89Zr-DBN with cell
surface membrane protein to form a stable covalent bond.
Efflux of 89Zr radioactivity from labeled cells
Retention of 89Zr radioactivity by 89Zr-DBN-labeled cells
was found to be stable in all the cells studied with negli-
gible efflux observed over 7 days post-labeling (Figure 4).
PET imaging and biodistribution studies in mice with
intravenous injections
PET images and biodistribution data of intravenously ad-
ministered 89Zr-labeled hMSCs and 89Zr(HPO4)2 in healthy
mice are shown in Figure 5. The 89Zr-labeled hMSCs were
concentrated primarily in the lung and liver, followed by
the bone. On the other hand, 89Zr(HPO4)2 accumulated in
the bone and liver and did not distribute to lung.
In vivo tracking of stem cell engraftment in ischemia/
reperfusion mouse model
Following myocardial delivery, 89Zr-labeled hMSCs (ap-
proximately 19.5% ± 9.5%) were retained for 7 days in
the heart (Figure 6). The remaining cells were concen-
trated in the lung, followed by the bones and liver. The
higher uptake in the lung relative to the liver is consist-
ent with the biodistribution of 89Zr-labeled hMSCs re-
leased into the circulation (Figure 5).
Discussion
Various strategies have been employed in the past to label
cells with imaging isotopes for non-invasive in vivo cell
tracking for cell-based therapies and infection imaging.
Among them, 18 F-FDG (for PET) [12-16] and 111In-oxine
(for SPECT) [2-6], are the most widely used. Although 18 F-
FDG is useful for assessment of immediate delivery of cells
and early fate of cells (approximately first few hours), it is
not suited for in vivo cell tracking after 24 h post-injection
due to its short half-life and poor retention in cells. Inability
of 18 F-FDG to allow cell tracking after 24 h limits its utility
in cell-based therapies. For cell-based therapies, early en-
graftment period of 2 to 5 weeks post cell delivery is the
most critical time period [20]. Therefore, imaging-based
methods should be robust over this time frame to allow
evaluation of various interventions for improving cell en-
graftment. The ability to monitor cells in vivo beyond 24 h
is also of high importance for evaluation of infection using
radiolabeled leukocytes. Conventional infection imaging
protocols perform imaging at 1, 4, and 24 h post-injection
to differentiate between inflammatory, acute infection, and
chronic infection loci; however, in some patients, 48 h was
necessary for reliable detection of infected lesions [21].
Figure 3 (See legend on next page.)
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Figure 3 Assessment of (A) viability, (B) cytotoxicity, and (C) apoptosis in 89Zr-labeled and unlabeled cells. No statistically significant
differences were observed between 89Zr-labeled and unlabeled cells after 7 days of culture with regard to viability, cytotoxicity, or apoptosis. As
positive controls, 30 μg/mL digitonin was used for assays (A) and (B), and 2 μΜ staurosporine for (C). *p < 0.05 versus assessments in 89Zr-labeled
and unlabeled cells using unpaired t-test. Values are shown as mean ± standard deviation, n = 3.
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cell labeling allows longer observation periods for cell
tracking but with lower spatial resolution of SPECT im-
aging. Cell labeling with 111In typically requires a lipo-
philic carrier molecule (e.g., oxine) for transporting the
radiometal into cells [2-6]. After entering the cells, the
radiometal then dissociates and gets trapped in the cell
by binding to non-specific intracellular metal-binding
proteins. The two major disadvantages of this approach
are chemotoxicity of the lipophilic carrier molecule [22]
and efflux of radiolabel from cells [2-6].
Recently, two groups (Charoenphun et al. [9] and
Davidson-Moncada et al. [10]) reported synthesis of 89Zr-
oxinate or 89Zr-oxine as a cell labeling reagent for PET-
based cell tracking. As expected, both groups faced the
problem of chemotoxicity and significant efflux of radio-
activity from the cells post-labeling commonly associated
with oxine-based labeling. Charoenphun et al. [9] showed
reduced viability of 89Zr-oxine-labeled 5 T33 myeloma cells
(from 93% to 76.3% ± 3.2% in the first 24 h) and significant
efflux of radioactivity post-labeling (29% effluxed in 24 h).
Davidson-Moncada et al. [10] also reported similar results
with 89Zr-oxine-labeled human and rhesus macaques’ nat-
ural killer cells. They observed a broad range of viability of
60% to 100% in the radiolabeled cells over the first 24 h,
which declined to 20% to 30% after 6 days. A significant ef-
flux of radioactivity was also observed in these viable 89Zr-
oxine-labeled cells, approximately 20% to 25% effluxed in
the first 24 h and 70% to 80% of radioactivity was effluxed
after 7 days of culture. These drawbacks associated with theFigure 4 Retention of 89Zr in 89Zr-labeled cells expressed as radioacti
representing total radioactivity/106 cells in the proliferating cell population
radiolabeled cells. Values are shown as mean ± standard deviation, n = 3.89Zr-oxine labeling method compromises its utility for
PET-based monitoring of in vivo cell trafficking.
To improve the stability of the 89Zr radiolabel on cells, we
proposed 89Zr-DFO-NCS (89Zr-DBN) as a labeling entity
capable of forming covalent bonds with primary amines of
cell surface protein (Figure 1). Since all cells express cell sur-
face protein with exposed lysine residues and other primary
amines, this strategy also provides a general labeling method
to label a broad array of cells. The new strategy exploits both
the strength of chelation of 89Zr by DFO with three hydro-
xamate groups (qualitative Zr-binding constant = approxi-
mately 1031) [23-26] as well as the inherent biostability of
the thiourea bond that conjugates NCS group in 89Zr-DBN
to primary amines of protein [27,28]. Furthermore, the label-
ing agent, 89Zr-DBN, is also expected to be well-tolerated by
cells as opposed to toxic lipophilic carrier molecules like
oxine, relying on the fact that DFO-NCS has been routinely
used to conjugate DFO to IgG and IgM antibodies with no
loss of antibody protein function [23,26-29]. The generality
of the labeling target, along with the multiplicity of primary
amines available on the cell surface, also avoids the specific
targeting of highly sensitive processes that might affect cellu-
lar function or viability. In contrast to the previously noted
89Zr-oxine results [9,10], no efflux of radiolabel was ob-
served from cultured cells labeled with 89Zr-DBN after re-
peated washing and culture with medium with 10% fetal
bovine serum (FBS) out to 7 days. These data strongly argue
for a covalent bonding of the radiolabel to the cells. Further-
more, in a subcellular fractionation study, essentially all 89Zr
radioactivity was incorporated into the membrane boundvity in MBq in the cell population. The retention value is
. No significant change was observed in retention of 89Zr in
Figure 5 Representative PET images and biodistribution data of 89Zr-labeled hMSCs and 89Zr(HPO4)2 following intravenous injection.
89Zr-labeled human MSCs (2 × 105 cells with radioactivity concentration approximately 0.37 MBq/106 cells) and 89Zr(HPO4)2 (approximately
0.074 MBq radioactivity) were intravenously injected in athymic mice. Most of the radioactivity was distributed in the lung, liver, and bones
following injection of 89Zr-labeled hMSCs whereas most of the radioactivity was distributed in the liver and bones following injection of 89Zr
(HPO4)2. Values in graphs are shown as mean ± standard deviation, n = 3.
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geting of membrane protein. The targeting of cell-surface
membrane protein also has the potential benefit of distan-
cing the labeling agent from potentially sensitive sites in the
cell. We found no evidence of chemotoxicity or radiotoxicity
effects of 89Zr-DBN labeling of three cell types in the present
study.Figure 6 Representative PET images and biodistribution data of 89Zr-
(2 × 105 cells with radioactivity concentration approximately 0.37 MBq/106
model. Most of the radioactivity was distributed in the heart (arrow), lung,
Values in graph are shown as mean ± standard deviation, n = 5.In this study, 30% to 50% labeling efficiencies were
achieved with 89Zr-DBN in several cell types. The cell la-
beling yield for mMCs, hMSCs, and mDCs were 0.50 ±
0.10, 0.47 ± 0.10, and 0.39 ± 0.20 MBq/106 cells for mMCs,
hMSCs, and mDCs, respectively. This is the maximum
load of radioactivity per 106 cells that we could achieve in
this study. In the clinical setting, approximately 108 cellslabeled hMSCs following myocardial delivery. 89Zr-labeled hMSCs
cells) were delivered to myocardium of an ischemia/reperfusion mouse
liver, and bones following myocardial delivery of 89Zr-labeled hMSCs.
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yield obtained in this study, the amount of 89Zr radioactiv-
ity administered to a patient would be in the range 30 to
50 MBq (0.8 to 1.4 mCi), which is in the range of 89Zr
radioactivity that is currently being used in patients with
89Zr-labeled antibodies.
After encouraging in vitro validation tests, we performed
in vivo validations by investigating the biodistribution of
89Zr-labeled hMSCs after intravenous injection in athymic
nude mice for 7 days post-injection. Trapping of MSCs in
the lungs following intravenous injection is well documented
[30,31]. Therefore, we expected major accumulation of 89Zr-
labeled human MSCs in mouse lungs following intravenous
injection with slow clearance. With time, cells were expected
to dislodge from this physical pulmonary entrapment and
distribute to other organs. As expected, the majority of
intravenously injected 89Zr-labeled hMSCs were trapped in
the lung (50%± 27%) and the remainder was found in the
liver (27% ± 19%) and bones (16%± 5%) after 7 days post-
injection, which are expected homing sites for injected mes-
enchymal stem cells after dislodging from the lung [32,33].
This was in contrast to the biodistribution of 89Zr(HPO4)2,
which distributed primarily in the bone (59% ± 13%) and
liver (32%± 15%) but did not accumulate in lungs. The dis-
tinct biodistributions of 89Zr-labeled hMSCs and 89Zr
(HPO4)2, together with the stability of radiolabel and lack of
cytotoxicity, strongly support the robustness of the 89Zr-
DBN-based cell labeling approach.
To further test the application of 89Zr-labeled hMSCs,
we performed a stem cell engraftment study using a myo-
cardial acute ischemia/reperfusion mouse model. 89Zr-la-
beled hMSCs were delivered to the myocardium of
athymic mice following an acute myocardial ischemia/re-
perfusion insult. After 7 days post-delivery, 89Zr-labeled
hMSCs were found in the heart (20% ± 7%), lung (40% ±
16%), bone (29% ± 11%), and liver (7% ± 5%). The ob-
served retention in the heart is in accordance with previ-
ously published work on hMSC engraftment estimated by
invasive quantitative PCR method in a similar rodent
model [34].
Low levels of in vitro demetalation of 89Zr-DFO com-
plexes (2% to 3%/week) in serum at 37°C have been re-
ported [23,29], and clinical studies using 89Zr-DFO-
labeled antibodies out to 7 days have yet to show signifi-
cant bone uptake of 89Zr indicative of demetalation
[35-39]. Our initial findings of distribution of 89Zr-la-
beled hMSCs in mouse models confirm the biostability
of the radiolabel bound to the DFO moiety supporting
further exploration of the 89Zr-DBN labeling method
for monitoring stem cell engraftment and cell traffick-
ing. Extension of this approach with the use of an alter-
native zirconium chelator, such as 3,4,3-[LI-1,2-HOPO]
[40] may further improve the biostability of the labeling
agent.Conclusions
The 89Zr-DBN labeling agent is shown to be a robust, gen-
eral, and biostable cell labeling strategy for PET-based non-
invasive in vivo cell tracking. To explore the full potential
of this approach, more work is needed to test this strategy
in various model systems and disease processes that are
germane to cell trafficking and stem cell therapies. We have
ongoing efforts to define the imaging sensitivity, biostability,
and toxicity parameters as the limits are pushed toward
higher 89Zr radioactivity loading of cells and longer obser-
vation periods in vivo.
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